Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...

Defining regions of genomic imbalance can identify genes involved in tumour development. Conventional cytogenetics has identified several nonrandom copy number alterations (CNA) in uveal melanomas ...

Clinical testing using various array comparative genomic hybridization platforms is being incorporated rapidly into cytogenetic testing algorithms. Comprehensive validation of these complex assays ...

The Cytogenetics Laboratory performs chromosome analysis, fluorescence in situ hybridization (FISH), and array comparative genomic hybridization (array CGH) on cells prepared from a wide variety of ...

Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408) ...

Array comparative genomic hybridization (CGH) is illuminating DNA copy number variations (CNV) throughout the genome to diagnose disease etiology and to help tailor treatment regimens for patients to ...

Recent advances in gene analysis technology have been remarkable, and many technologies that can be easily introduced in each in-house laboratory have been developed. Especially a comprehensive gene ...

Predictors of survival in advanced renal cell carcinoma (RCC): Long-term results from Southwest Oncology Group trial S8949 No significant financial relationships to disclose. This is an ASCO Meeting ...

DUBLIN--(BUSINESS WIRE)--The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Molecular Cytogenetics Market to Reach $3.5 ...